GET DAILY SIGNALSWhy Is Alamar Biosciences (ALMR) Stock Down -12.41% Today?
Key Takeaways
- Shares of ALMR fell roughly 12.4% in early trading, sliding from a prior close of $30.22 to about $26.47.
- The decline followed third-quarter 2026 results that beat estimates and raised full-year guidance but signaled flat sequential fourth-quarter revenue.
- Leadership uncertainty added pressure after President Tod White announced plans to retire at year-end.
- Widening losses and surging operating expenses weighed on sentiment despite record gross margins.
- Continued insider selling by pre-IPO backer Qiming added supply overhang to the stock.
- Traders are watching Q4 instrument placements, consumables pull-through, and any further holder disclosures.
- For deeper analysis, explore Price Targets, Earnings, and Forecast pages.
- Looking for actionable ideas? Explore the Trending AI Robots section.
Opening Summary
Alamar Biosciences, Inc. (ALMR), a Fremont, California-based precision proteomics company that sells its NULISA technology and ARGO HT instrument system for biomarker detection and early disease research, tumbled in Tuesday's session. Shares were down about 12.41% to roughly $26.47, compared with a prior close of $30.22. The slide came as the market digested the company's third-quarter report released after the close on November 3, which beat top- and bottom-line expectations but offered guidance implying flat sequential growth, alongside the announcement of a key leadership transition.
Earnings Beat and Raise, but Guidance Signals a Slowdown
At first glance, Alamar's Q3 results looked constructive. Total revenue grew 68% year over year to $33.55 million, driven by a 79% jump in consumables, and the company posted a narrower-than-expected loss of $0.19 per share versus the $0.22 consensus. Gross margin reached a record 61.5%, and management raised its full-year 2026 revenue guidance to a range of $121 million to $123 million, up from $116 million to $120 million.
Yet the market reaction focused on the forward curve. At the midpoint, the new guidance implied essentially flat sequential revenue in the fourth quarter, a deceleration that raised questions about near-term momentum. Management attributed the softness to large, non-recurring custom assay development projects within its Technology Access Program that are not expected to repeat at the same level, while the company refrained from breaking out quarterly sample-volume expectations for large studies. For a stock priced at a premium multiple, that lack of visibility proved enough to trigger selling.
Leadership Transition Adds Uncertainty
Compounding the pressure, Alamar disclosed that President Tod White will retire at the end of 2026, remaining as an advisor through mid-2027. White, who joined in 2021 and helped scale operations and steer the company through its April 2026 initial public offering, is a familiar figure to investors. Departures at the executive level, particularly at a young, high-growth public company, often inject an element of uncertainty into the investment thesis, and the announcement coincided with a session already leaning cautious.
Widening Losses and Insider Selling Pressure
The quarter also highlighted rising costs. Net loss widened to $13.3 million from $8.0 million a year earlier, and operating loss expanded to $15.1 million from $7.9 million, reflecting sharply higher selling, general and administrative, and research and development expenses tied to headcount, infrastructure, and public-company costs. At the same time, regulatory filings showed that entities affiliated with pre-IPO investor Qiming continued to sell shares in late October and early November, adding to the supply overhang and reinforcing investor caution about valuation.
Market Context and Trading Activity
The price decline took ALMR back below the levels it traded at before its recent earnings-driven rally, unwinding the roughly 4.4% gain posted on November 3. The stock has now retreated meaningfully from its 52-week high, reflecting a broader risk-off tone toward high-multiple, early-stage life science tools names. Trading volume picked up as the session began, consistent with investors repositioning in the wake of the report, while the move diverged from the steadier performance of large-cap indices.
What Comes Next for ALMR
Investors will now look for evidence that the fourth-quarter guidance is conservative rather than a sign of stalling adoption. Key watch items include the pace of instrument placements, consumables pull-through above $400,000 per instrument, and the ramp of large-scale studies with partners such as the UK Biobank and GSK, which are expected to contribute more meaningfully in 2027. The company's ability to convert its growing installed base into recurring consumables revenue, alongside its path toward profitability, remains central to the story. Risks include further insider selling, execution around the leadership transition, and the inherent volatility of a recently listed, high-growth stock still trading well above its IPO price.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of automated approaches to consider. Explore the section to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALMR in downward trend: price dove below 50-day moving average on October 30, 2026
ALMR moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend. In 1 of 1 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ALMR moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In 3 of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at 60%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 4 of 5 cases where ALMR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on ALMR as a result. In 8 of 8 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for ALMR just turned positive on October 21, 2026. Looking at past instances where ALMR's MACD turned positive, the stock continued to rise in 2 of 2 cases over the following month. The odds of a continued upward trend are 90%.
Following a +12.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALMR advanced for three days, in 30 of 32 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
ALMR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.703) is normal, around the industry mean (4.170). P/E Ratio (-42.224) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (20.367) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. ALMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALMR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement